Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
- Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion
- Memorial Sloan Kettering collaborators presented positive Phase 2 clinical results for EBV-specific T cells in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) involving the central nervous system (CNS)
- PTLD patient treatment patterns and health outcomes are described in additional ASH presentations